<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102305</url>
  </required_header>
  <id_info>
    <org_study_id>BR-NAC-OS-402</org_study_id>
    <nct_id>NCT05102305</nct_id>
  </id_info>
  <brief_title>A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)</brief_title>
  <official_title>A Multi-center, Prospective, Observational Study to Evaluate the Effectiveness of N-acetylcysteine (NAC) Nebulizer Therapy (Mucomyst Solution) in COPD With Difficulty of Expectoration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of Mucomyst nebulizer therapy on improvement in symptoms and quality&#xD;
      of life in COPD patients with difficulty of expectoration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this non-interventional observational study, treatment for individual subjects is&#xD;
      determined by the investigator according to the status of individual subjects in routine&#xD;
      clinical practice. In this circumstance, doses for each drug product will not be specified in&#xD;
      the protocol but will be determined as appropriate by the investigator with the product label&#xD;
      and the subject's medical condition taken into consideration.&#xD;
&#xD;
      Primary objective To evaluate the effect of Mucomyst on improvement in difficulty of&#xD;
      expectoration symptoms in COPD patients with difficulty of expectoration.&#xD;
&#xD;
      Secondary objective To evaluate the effect of Mucomyst on improvement in quality of life and&#xD;
      safety in COPD patients with difficulty of expectoration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 16, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in CAT</measure>
    <time_frame>at Week 12</time_frame>
    <description>Change from baseline in CAT phlegm score at Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CAT</measure>
    <time_frame>at Weeks 4 and 8</time_frame>
    <description>Change from baseline in CAT phlegm score at Weeks 4 and 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CAT</measure>
    <time_frame>at Weeks 4, 8,and 12</time_frame>
    <description>Change from baseline in CAT total score and sub-scale score at Weeks 4, 8, and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SGRQ-C</measure>
    <time_frame>at Weeks 4, 8, and 12</time_frame>
    <description>Change from baseline in St. George's Respiratory Questionnaire for COPD patients (SGRQ-C) total score at Weeks 4, 8, and 12</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Obstructive Pulmonary Disease (COPD) patients with Difficulty of Expectoration.&#xD;
        Total 100 subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. man and woman at the age of ≥40 years old&#xD;
&#xD;
          2. Diagnosed with COPD within the past 1 year based on pulmonary function test (post&#xD;
             bronchodilator FEV1/FVC&lt;0.7)&#xD;
&#xD;
          3. COPD Assessment Test (CAT) phlegm score ≥2&#xD;
&#xD;
          4. Smoking history ≥10 pack-years* (*Pack-year: number of packs of cigarettes smoked per&#xD;
             day X number of years the individual has smoked)&#xD;
&#xD;
          5. Patient who is to be treated with Mucomyst nebulizer therapy to alleviate difficulty&#xD;
             of expectoration symptoms&#xD;
&#xD;
          6. Voluntary written informed consent to study participation and to use of personal&#xD;
             information for this study&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. History of hypersensitivity reactions to any of the components of NAC or&#xD;
             contraindicated to NAC therapy according to the product label&#xD;
&#xD;
          2. Treated with Mucomyst within the past 4 weeks&#xD;
&#xD;
          3. Newly treated with 'drugs for the alleviation of expectoration symptoms&#xD;
             (antitussives/expectorants)' or dose changed for ongoing therapy within the past 4&#xD;
             weeks&#xD;
&#xD;
          4. Pregnant and lactating woman&#xD;
&#xD;
          5. Participating in another trial with investigational product treatment at the time of&#xD;
             enrollment to the present study&#xD;
&#xD;
          6. Ineligible for study participation in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyo.Jae Kim</last_name>
    <phone>82-2-708-8203</phone>
    <email>igniter@boryung.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Konkuk University medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwang Ha Yoo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

